Influenza cases
STO-REC-STAT01M2KJT2 National
1 billion
Global · 2026
Influenza cases stood at 1 billion in 2026 (GSK).
- Publisher
- GSK
- Authority tier
- T2 National
- Report
- GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data
- Locator
- About seasonal flu
- Retrieved
- 15 Sep 2026
- Status
- Verified
What the source says
Seasonal influenza causes around one billion cases globally each year, including up to 5 million cases of severe illness and up to 650,000 respiratory deaths.
Verbatim extraction verified: The figure 1 billion is directly attested in the quoted passage (About seasonal flu).
The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.
Cite this figure
Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.
- APA
- GSK. (2026). GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data. Retrieved September 15, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-to-advance-mrna-seasonal-flu-vaccine-candidate-to-phase-iii-following-positive-phase-ii-data/. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGF
- MLA
- GSK. "GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data." 2026, https://www.gsk.com/en-gb/media/press-releases/gsk-to-advance-mrna-seasonal-flu-vaccine-candidate-to-phase-iii-following-positive-phase-ii-data/. Accessed 15 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGF.
- Chicago
- GSK. "GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data." 2026. https://www.gsk.com/en-gb/media/press-releases/gsk-to-advance-mrna-seasonal-flu-vaccine-candidate-to-phase-iii-following-positive-phase-ii-data/. Accessed September 15, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGF.
- BibTeX
- @misc{gsk2026influenzabjmggf, author = {{GSK}}, title = {GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data}, year = {2026}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGF}, note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-to-advance-mrna-seasonal-flu-vaccine-candidate-to-phase-iii-following-positive-phase-ii-data/. Accessed September 15, 2026.} }
Provenance and verification
Everything needed to check this number yourself, without taking our word for it.
Chain of Custody · Verification Audit
Primary Source
- Publisher
- GSK · homepage ↗
- Authority tier
- Tier 2 · National Official
- Report
- GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data
- Type
- Press release
- Published
- —
- Locator
- About seasonal flu
- Retrieved
- 15 September 2026
- Link status
- Reachable (HTTP 200)
- Report licence
- See source
Verification & Integrity
- Audit status
- Verified
- Review protocol
- Editorial review
- Checked on
- 15 September 2026
- Last revision
- 15 September 2026
- Archival URI
- /stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGF